Jung Minji, Choo Eunjung, Li Shufeng, Deng Zhengyi, Li Jinhui, Li Mingyi, Basran Satvir, Lee Sukhyang, Langston Marvin E, Chung Benjamin I
Department of Urology, Stanford University Medical Center, Stanford, CA, United States.
Department of Clinical Pharmacy, School of Pharmacy, Ajou University, Suwon, Republic of Korea.
Front Oncol. 2024 Jul 12;14:1420333. doi: 10.3389/fonc.2024.1420333. eCollection 2024.
Cardiovascular disease (CVD) is a major concern of morbidity and mortality among cancer survivors. However, few evidence exists on the short- and long-term risk of CVD in kidney cancer (KCa) survivors.
In this nationwide, large population-based retrospective cohort study, we used the Korean national health insurance and medical checkup survey linkage database (2007-2021), drawn from the entire Korean population. We included adults diagnosed with KCa as the first primary cancer and matched them to an individual without KCa at a 1:5 ratio. The primary outcome was CVD incidence, including myocardial infarction, stroke, atrial fibrillation, heart failure, peripheral arterial occlusion, and venous thromboembolism (VTE). We evaluated CVD risk at 6 months, 1 year, and 5 years following cancer diagnosis, using Fine-Gray competing risk models that accounted for death as a competing factor.
A total of 149,232 participants were included (KCa survivors: N=20,093 and matched non-KCa individuals: N=129,139). After 6-month follow-up, KCa survivors showed an increased risk of CVD compared to the general population (subdistribution hazard ratio (HR) 2.70, 95% confidence interval (CI) 2.31-3.15). After 1 year, KCa survivors had a higher risk of CVD (HR=1.77, 95% CI: 1.56-2.00). After 5 years, this elevated CVD risk remained (HR=1.10, 95% CI: 1.03-1.18), with VTE identified as the primary contributing disease (HR=3.05, 95% CI:2.59-3.59).
KCa survivors had an increased risk of CVD up to 5 years after cancer diagnosis compared to the general population. Our findings emphasize the importance of comprehensive healthcare management for both CVD and KCa throughout cancer survivorship.
心血管疾病(CVD)是癌症幸存者发病和死亡的主要关注点。然而,关于肾癌(KCa)幸存者发生CVD的短期和长期风险的证据很少。
在这项全国性的、基于大人群的回顾性队列研究中,我们使用了韩国国民健康保险和体检调查关联数据库(2007 - 2021年),该数据库来自全体韩国人群。我们纳入了被诊断为KCa作为首个原发性癌症的成年人,并以1:5的比例将他们与未患KCa的个体进行匹配。主要结局是CVD发病率,包括心肌梗死、中风、心房颤动、心力衰竭、外周动脉闭塞和静脉血栓栓塞(VTE)。我们使用考虑死亡作为竞争因素的Fine - Gray竞争风险模型,评估癌症诊断后6个月、1年和5年时的CVD风险。
总共纳入了149,232名参与者(KCa幸存者:N = 20,093,匹配的非KCa个体:N = 129,139)。经过6个月的随访,与普通人群相比,KCa幸存者发生CVD的风险增加(亚分布风险比(HR)2.70,95%置信区间(CI)2.31 - 3.15)。1年后,KCa幸存者发生CVD的风险更高(HR = 1.77,95% CI:1.56 - 2.00)。5年后,这种CVD风险仍然升高(HR = 1.10,95% CI:1.03 - 1.18),VTE被确定为主要的致病疾病(HR = 3.05,95% CI:2.59 - 3.59)。
与普通人群相比,KCa幸存者在癌症诊断后的5年内发生CVD的风险增加。我们的研究结果强调了在整个癌症幸存者阶段对CVD和KCa进行综合医疗管理的重要性。